Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Tarsus Pharmaceuticals (TARS) Debt to Equity (2022 - 2025)

Historic Debt to Equity for Tarsus Pharmaceuticals (TARS) over the last 4 years, with Q3 2025 value amounting to $0.22.

  • Tarsus Pharmaceuticals' Debt to Equity fell 2856.03% to $0.22 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.22, marking a year-over-year decrease of 2856.03%. This contributed to the annual value of $0.32 for FY2024, which is 11137.87% up from last year.
  • As of Q3 2025, Tarsus Pharmaceuticals' Debt to Equity stood at $0.22, which was down 2856.03% from $0.22 recorded in Q2 2025.
  • Tarsus Pharmaceuticals' 5-year Debt to Equity high stood at $0.32 for Q4 2024, and its period low was $0.09 during Q2 2022.
  • Its 4-year average for Debt to Equity is $0.18, with a median of $0.15 in 2023.
  • As far as peak fluctuations go, Tarsus Pharmaceuticals' Debt to Equity surged by 11716.57% in 2024, and later crashed by 2856.03% in 2025.
  • Over the past 4 years, Tarsus Pharmaceuticals' Debt to Equity (Quarter) stood at $0.1 in 2022, then skyrocketed by 50.25% to $0.15 in 2023, then soared by 111.38% to $0.32 in 2024, then crashed by 32.58% to $0.22 in 2025.
  • Its Debt to Equity was $0.22 in Q3 2025, compared to $0.22 in Q2 2025 and $0.21 in Q1 2025.